Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Ny viden om prognose for og behandling af börneabsenceepilepsi
Engelsk titel: Scientific evidence on treatment and prognosis of childhood absence epilepsy Läs online Författare: Bloch, Joakim ; Miranda, Maria J Språk: Dan Antal referenser: 30 Dokumenttyp: Översikt UI-nummer: 18010400

Tidskrift

Ugeskrift for Laeger 2017;179(24)2113-7 ISSN 0041-5782 E-ISSN 1603-6824 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

Until now, ethosuximide (ESM), sodium valproate (VPA) and lamotrigine have been considered the drugs of choice in the management of childhood absence epilepsy, and there has been no high-validated evidence to distinguish their effects. New research shows, however, that while VPA and ESM are equally effective, ESM is the best tolerated of the two drugs, when considering cognitive adverse effects. This is of major importance, as cognitive comorbidities can be dire in childhood absence epilepsy, possibly affecting the psychosocial prognosis of the patients. More research is needed in this area.